| Methods |
Randomisation sequence: method of generation not reported. Allocation concealment: method not reported. No information reported on completion of treatment as per protocol in all patients neither on the number of patients lost to the follow‐up. Follow‐up 30 days. Intention‐to‐treat analysis not assessable. |
| Participants |
Country: Pakistan. Cirrhotic patients with endoscopy‐proven variceal bleeding. Aetiology mostly HBV and HCV.
Exclusion: bleeding from causes different from oesophageal varices;HCC; age more than 75; non cirrhotic portal hypertension. |
| Interventions |
EVS: intra injection 4 to 6 ml of 50% ethanolamine on day 1,8,15,29;max volume per session not reported.
Control: 48‐hour continuous iv infusion of octreotide 50 µg/h followed by subcutaneous 50 µg injections every eight hours for 3 days. |
| Outcomes |
4‐hour control of bleeding; early re‐bleeding; 30‐day re‐bleeding; 30‐day mortality. |
| Notes |
This is a three group randomised trial: EVS, EVS plus octreotide, octreotide alone. Only the two groups, ie, EVS vs octreotide are of interest to this review. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Unclear |
| Allocation concealment? |
Unclear risk |
Unclear |
